AZ inks $250M Zoladex deal in latest closet cleanout by Tracy Staton Tuesday, February 21, 2017 AstraZeneca snagged $250 million-plus for its cancer drug Zoladex in the U.S., where it brought in only $69 million last year. The deal, AZ's latest slim-down maneuver, also includes a share of ongoing sales.
